KLK3 and benign prostatic hyperplasia: This set of experiments clearly showed that IC-ELISA was able to measure significantly higher plasmatic levels of Exo-PSA in patients with PCa as compared to both healthy controls (100% specificity and 100% sensitivity, perfect classifier 1.00) and patients with BPH (98.57% specificity and 80.28% sensitivity, 0.98 AUC).